WO2009095742A1
(en)
|
2008-01-31 |
2009-08-06 |
Cellectis |
New i-crei derived single-chain meganuclease and uses thereof
|
WO2004067753A2
(en)
|
2003-01-28 |
2004-08-12 |
Cellectis |
Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof.
|
WO2006097853A1
(en)
|
2005-03-15 |
2006-09-21 |
Cellectis |
I-crei meganuclease variants with modified specificity, method of preparation and uses thereof
|
WO2009019528A1
(en)
*
|
2007-08-03 |
2009-02-12 |
Cellectis |
Meganuclease variants cleaving a dna target sequence from the human interleukin-2 receptor gamma chain gene and uses thereof
|
EP3578646A3
(de)
|
2007-10-31 |
2020-03-18 |
Precision Biosciences, Inc. |
Rational konstruierte einzelketten-meganukleasen mit nicht-palindrom-erkennungssequenzen
|
WO2009074842A1
(en)
*
|
2007-12-13 |
2009-06-18 |
Cellectis |
Improved chimeric meganuclease enzymes and uses thereof
|
WO2009114321A2
(en)
|
2008-03-11 |
2009-09-17 |
Precision Biosciencs, Inc. |
Rationally-designed meganucleases for maize genome engineering
|
EP3495478A3
(de)
|
2008-07-14 |
2019-07-24 |
Precision Biosciences, Inc. |
Erkennungssequenzen für meganukleasen aus i-crei und ihre verwendung
|
CN102177235A
(zh)
*
|
2008-09-08 |
2011-09-07 |
赛莱克蒂斯公司 |
切割来自谷氨酰胺合成酶基因的dna靶序列的大范围核酸酶变体及其用途
|
EP2180058A1
(de)
|
2008-10-23 |
2010-04-28 |
Cellectis |
Meganuklease-Rekombinationssystem
|
US20120171191A1
(en)
|
2009-05-26 |
2012-07-05 |
Cellectis |
Meganuclease variants cleaving the genome of a pathogenic non-integrating virus and uses thereof
|
WO2011007193A1
(en)
|
2009-07-17 |
2011-01-20 |
Cellectis |
Viral vectors encoding a dna repair matrix and containing a virion-associated site specific meganuclease for gene targeting
|
WO2011021062A1
(en)
|
2009-08-21 |
2011-02-24 |
Cellectis |
Meganuclease variants cleaving a dna target sequence from the human lysosomal acid alpha-glucosidase gene and uses thereof
|
WO2011036640A2
(en)
|
2009-09-24 |
2011-03-31 |
Cellectis |
Meganuclease reagents of uses thereof for treating genetic diseases caused by frame shift/non sense mutations
|
US20130227715A1
(en)
*
|
2010-02-26 |
2013-08-29 |
Cellectis |
Use of endonucleases for inserting transgenes into safe harbor loci
|
CA2799095A1
(en)
|
2010-05-12 |
2011-11-17 |
Cellectis |
Meganuclease variants cleaving a dna target sequence from the dystrophin gene and uses thereof
|
EP2569435A1
(de)
*
|
2010-05-12 |
2013-03-20 |
Cellectis |
Eine dna-zielsequenz von einem rhodopsin-gen abspaltende meganukleasevarianten und ihre verwendung
|
EP2582845A2
(de)
*
|
2010-06-15 |
2013-04-24 |
Cellectis |
Verfahren zur verbesserung einer dna-spaltung durch für methylierung empfindliche endonuklease
|
CA2804249A1
(en)
|
2010-07-07 |
2012-01-12 |
Cellectis |
Meganucleases variants cleaving a dna target sequence in the nanog gene and uses thereof
|
WO2012010976A2
(en)
*
|
2010-07-15 |
2012-01-26 |
Cellectis |
Meganuclease variants cleaving a dna target sequence in the tert gene and uses thereof
|
WO2012007848A2
(en)
|
2010-07-16 |
2012-01-19 |
Cellectis |
Meganuclease variants cleaving a dna target sequence in the was gene and uses thereof
|
JP2013544082A
(ja)
|
2010-10-27 |
2013-12-12 |
セレクティス |
二本鎖破断−誘導変異誘発の効率を増大させる方法
|
US9044492B2
(en)
|
2011-02-04 |
2015-06-02 |
Cellectis Sa |
Method for modulating the efficiency of double-strand break-induced mutagenesis
|
SG10201602651YA
(en)
|
2011-04-05 |
2016-05-30 |
Cellectis |
Method for the generation of compact tale-nucleases and uses thereof
|
WO2012138901A1
(en)
|
2011-04-05 |
2012-10-11 |
Cellectis Sa |
Method for enhancing rare-cutting endonuclease efficiency and uses thereof
|
WO2012158778A1
(en)
|
2011-05-16 |
2012-11-22 |
Cellectis S.A. |
Doubly secure transgenic algae or cyanobacteria strains to prevent their establishment and spread in natural ecosystems
|
WO2013009525A1
(en)
|
2011-07-08 |
2013-01-17 |
Cellectis S.A. |
Method for increasing the efficiency of double-strand break-induced mutagenssis
|
EP3327127B1
(de)
|
2012-12-12 |
2021-03-24 |
The Broad Institute, Inc. |
Ausgabe, bearbeitung und optimierung von systemen, verfahren und zusammensetzungen zur sequenzmanipulation und therapeutische anwendungen
|
WO2014093701A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
|
CN103173491A
(zh)
*
|
2013-03-15 |
2013-06-26 |
中国人民解放军第三军医大学 |
融合蛋白NLS-I-SceI在制备介导哺乳动物基因转移的试剂中的应用
|
RU2716420C2
(ru)
|
2013-06-17 |
2020-03-11 |
Те Брод Инститьют Инк. |
Доставка и применение систем crispr-cas, векторов и композиций для целенаправленного воздействия и терапии в печени
|
MX2015017311A
(es)
|
2013-06-17 |
2017-04-10 |
Broad Inst Inc |
Suministro, modificación y optimización de sistemas, métodos y composiciones para generar modelos y actuar sobre enfermedades y trastornos de células posmitóticas.
|
JP6702858B2
(ja)
|
2013-06-17 |
2020-06-03 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
ウイルス成分を使用して障害および疾患をターゲティングするためのCRISPR−Cas系および組成物の送達、使用および治療上の適用
|
RU2016128077A
(ru)
|
2013-12-12 |
2018-12-06 |
Те Брод Инститьют Инк. |
Доставка, применение и применения в терапии систем и композиций crispr-cas для лечения обусловленных hbv и вирусных заболеваний и нарушений
|
CN106536729A
(zh)
|
2013-12-12 |
2017-03-22 |
布罗德研究所有限公司 |
使用粒子递送组分靶向障碍和疾病的crispr‑cas系统和组合物的递送、用途和治疗应用
|
WO2015089486A2
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
|
WO2016049163A2
(en)
|
2014-09-24 |
2016-03-31 |
The Broad Institute Inc. |
Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder
|
WO2016049251A1
(en)
|
2014-09-24 |
2016-03-31 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling mutations in leukocytes
|
EP3212788A2
(de)
|
2014-10-27 |
2017-09-06 |
The Broad Institute, Inc. |
Zusammensetzungen, verfahren und verwendung von screening auf synthetische tödliche gene
|
WO2016094872A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Dead guides for crispr transcription factors
|
WO2016094874A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Escorted and functionalized guides for crispr-cas systems
|
EP3985115A1
(de)
|
2014-12-12 |
2022-04-20 |
The Broad Institute, Inc. |
Geschützte guide-rnas (pgrnas)
|
AU2015369725A1
(en)
|
2014-12-24 |
2017-06-29 |
Massachusetts Institute Of Technology |
CRISPR having or associated with destabilization domains
|
WO2016108926A1
(en)
|
2014-12-30 |
2016-07-07 |
The Broad Institute Inc. |
Crispr mediated in vivo modeling and genetic screening of tumor growth and metastasis
|
WO2016205728A1
(en)
|
2015-06-17 |
2016-12-22 |
Massachusetts Institute Of Technology |
Crispr mediated recording of cellular events
|
US9790490B2
(en)
|
2015-06-18 |
2017-10-17 |
The Broad Institute Inc. |
CRISPR enzymes and systems
|
CA3012607A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Crispr enzymes and systems
|
EP3666895A1
(de)
|
2015-06-18 |
2020-06-17 |
The Broad Institute, Inc. |
Neuartige crispr-enzyme und systeme
|
SG10201912329YA
(en)
|
2015-06-18 |
2020-02-27 |
Broad Inst Inc |
Crispr Enzyme Mutations Reducing Off-Target Effects
|
US20190255107A1
(en)
|
2015-10-09 |
2019-08-22 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
CN116814590A
(zh)
|
2015-10-22 |
2023-09-29 |
布罗德研究所有限公司 |
Vi-b型crispr酶和系统
|
WO2017074788A1
(en)
|
2015-10-27 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for targeting cancer-specific sequence variations
|
WO2017075478A2
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
|
WO2017075451A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
|
WO2017075465A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
|
WO2017079428A1
(en)
|
2015-11-04 |
2017-05-11 |
President And Fellows Of Harvard College |
Site specific germline modification
|
WO2017106657A1
(en)
|
2015-12-18 |
2017-06-22 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
WO2017189308A1
(en)
|
2016-04-19 |
2017-11-02 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
JP7267013B2
(ja)
|
2016-06-17 |
2023-05-01 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
Vi型crisprオルソログ及び系
|
WO2018005873A1
(en)
|
2016-06-29 |
2018-01-04 |
The Broad Institute Inc. |
Crispr-cas systems having destabilization domain
|
WO2018035250A1
(en)
|
2016-08-17 |
2018-02-22 |
The Broad Institute, Inc. |
Methods for identifying class 2 crispr-cas systems
|
WO2018035364A1
(en)
|
2016-08-17 |
2018-02-22 |
The Broad Institute Inc. |
Product and methods useful for modulating and evaluating immune responses
|
US20190262399A1
(en)
|
2016-09-07 |
2019-08-29 |
The Broad Institute, Inc. |
Compositions and methods for evaluating and modulating immune responses
|
WO2018067991A1
(en)
|
2016-10-07 |
2018-04-12 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
WO2018107129A1
(en)
|
2016-12-09 |
2018-06-14 |
The Broad Institute, Inc. |
Crispr effector system based diagnostics
|
WO2018170340A1
(en)
|
2017-03-15 |
2018-09-20 |
The Broad Institute, Inc. |
Crispr effector system based diagnostics for virus detection
|
KR102185464B1
(ko)
|
2017-03-15 |
2020-12-03 |
매사추세츠 인스티튜트 오브 테크놀로지 |
신규 cas13b 오르소로그 crispr 효소 및 시스템
|
US11174515B2
(en)
|
2017-03-15 |
2021-11-16 |
The Broad Institute, Inc. |
CRISPR effector system based diagnostics
|
US11963966B2
(en)
|
2017-03-31 |
2024-04-23 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating ovarian tumors
|
US11913075B2
(en)
|
2017-04-01 |
2024-02-27 |
The Broad Institute, Inc. |
Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
|
WO2018191553A1
(en)
|
2017-04-12 |
2018-10-18 |
Massachusetts Eye And Ear Infirmary |
Tumor signature for metastasis, compositions of matter methods of use thereof
|
AU2018251801A1
(en)
|
2017-04-12 |
2019-11-07 |
Massachusetts Institute Of Technology |
Novel type VI crispr orthologs and systems
|
US11618928B2
(en)
|
2017-04-12 |
2023-04-04 |
The Broad Institute, Inc. |
CRISPR effector system based diagnostics for malaria detection
|
US11072816B2
(en)
|
2017-05-03 |
2021-07-27 |
The Broad Institute, Inc. |
Single-cell proteomic assay using aptamers
|
EP3638218A4
(de)
|
2017-06-14 |
2021-06-09 |
The Broad Institute, Inc. |
Zusammensetzungen und verfahren zum targeting von komplementierender komponente 3 zur hemmung des tumorwachstums
|
WO2019014581A1
(en)
|
2017-07-14 |
2019-01-17 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF A CYTOTOXIC LYMPHOCYTE
|
US12105089B2
(en)
|
2017-07-17 |
2024-10-01 |
The Broad Institute, Inc. |
Cell atlas of the healthy and ulcerative colitis human colon
|
US11130999B2
(en)
|
2017-07-31 |
2021-09-28 |
Regeneron Pharmaceuticals, Inc. |
Cas-ready mouse embryonic stem cells and mice and uses thereof
|
AU2018309714A1
(en)
|
2017-07-31 |
2020-01-30 |
Regeneron Pharmaceuticals, Inc. |
Assessment of CRISPR/Cas-induced recombination with an exogenous donor nucleic acid in vivo
|
WO2019028023A2
(en)
|
2017-07-31 |
2019-02-07 |
Regeneron Pharmaceuticals, Inc. |
METHODS AND COMPOSITIONS FOR EVALUATING CRISPR / CAS MEDIATED DISRUPTION OR EXCISION AND CRISPR / CAS INDUCED RECOMBINATION USING IN VIVO EXOGENIC DONOR NUCLEIC ACID
|
US12043870B2
(en)
|
2017-10-02 |
2024-07-23 |
The Broad Institute, Inc. |
Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
|
WO2019079362A1
(en)
|
2017-10-16 |
2019-04-25 |
Massachusetts Institute Of Technology |
HOST-PATHOGENIC INTERACTION OF MYCOBACTERIUM TUBERCULOSIS
|
WO2019094983A1
(en)
|
2017-11-13 |
2019-05-16 |
The Broad Institute, Inc. |
Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway
|
WO2019113506A1
(en)
|
2017-12-07 |
2019-06-13 |
The Broad Institute, Inc. |
Methods and compositions for multiplexing single cell and single nuclei sequencing
|
US11994512B2
(en)
|
2018-01-04 |
2024-05-28 |
Massachusetts Institute Of Technology |
Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
|
EP3746568B1
(de)
|
2018-01-29 |
2023-11-15 |
The Broad Institute, Inc. |
Auf crispr-effektor-system basierende diagnose
|
AU2019239880B2
(en)
|
2018-03-19 |
2023-11-30 |
Regeneron Pharmaceuticals, Inc. |
Transcription modulation in animals using CRISPR/Cas systems
|
US11957695B2
(en)
|
2018-04-26 |
2024-04-16 |
The Broad Institute, Inc. |
Methods and compositions targeting glucocorticoid signaling for modulating immune responses
|
US20210147831A1
(en)
|
2018-04-27 |
2021-05-20 |
The Broad Institute, Inc. |
Sequencing-based proteomics
|
US20210371932A1
(en)
|
2018-06-01 |
2021-12-02 |
Massachusetts Institute Of Technology |
Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
|
US12036240B2
(en)
|
2018-06-14 |
2024-07-16 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
MX2020013461A
(es)
|
2018-06-26 |
2021-04-28 |
Broad Inst Inc |
Composiciones, sistemas y métodos de amplificación basados en la doble nicasa crispr.
|
EP3830256A2
(de)
|
2018-07-31 |
2021-06-09 |
The Broad Institute, Inc. |
Neuartige crispr-enzyme und systeme
|
US20210317429A1
(en)
|
2018-08-20 |
2021-10-14 |
The Broad Institute, Inc. |
Methods and compositions for optochemical control of crispr-cas9
|
US20210324357A1
(en)
|
2018-08-20 |
2021-10-21 |
The Brigham And Women's Hospital, Inc. |
Degradation domain modifications for spatio-temporal control of rna-guided nucleases
|
US20210355522A1
(en)
|
2018-08-20 |
2021-11-18 |
The Broad Institute, Inc. |
Inhibitors of rna-guided nuclease activity and uses thereof
|
KR20210070305A
(ko)
|
2018-09-18 |
2021-06-14 |
브이엔브이 뉴코 인크. |
Arc 기반 캡시드 및 이의 용도
|
WO2020072816A1
(en)
|
2018-10-03 |
2020-04-09 |
The Broad Institute, Inc. |
Crispr effector system based diagnostics for hemorrhagic fever detection
|
US20220401460A1
(en)
|
2018-10-10 |
2022-12-22 |
Dana-Farber Cancer Institute, Inc. |
Modulating resistance to bcl-2 inhibitors
|
WO2020077236A1
(en)
|
2018-10-12 |
2020-04-16 |
The Broad Institute, Inc. |
Method for extracting nuclei or whole cells from formalin-fixed paraffin-embedded tissues
|
WO2020081730A2
(en)
|
2018-10-16 |
2020-04-23 |
Massachusetts Institute Of Technology |
Methods and compositions for modulating microenvironment
|
US20220073987A1
(en)
|
2018-11-14 |
2022-03-10 |
The Broad Institute, Inc. |
Crispr system based droplet diagnostic systems and methods
|
JP2022507573A
(ja)
|
2018-11-14 |
2022-01-18 |
プレジデント アンド フェロウズ オヴ ハーヴァード カレッジ |
Sherlockによる高度に進化するウイルスバリアントの多重化
|
WO2020124050A1
(en)
|
2018-12-13 |
2020-06-18 |
The Broad Institute, Inc. |
Tiled assays using crispr-cas based detection
|
CA3124110A1
(en)
|
2018-12-17 |
2020-06-25 |
The Broad Institute, Inc. |
Crispr-associated transposase systems and methods of use thereof
|
US11739156B2
(en)
|
2019-01-06 |
2023-08-29 |
The Broad Institute, Inc. Massachusetts Institute of Technology |
Methods and compositions for overcoming immunosuppression
|
WO2020186231A2
(en)
|
2019-03-14 |
2020-09-17 |
The Broad Institute, Inc. |
Crispr effector system based multiplex diagnostics
|
WO2020191102A1
(en)
|
2019-03-18 |
2020-09-24 |
The Broad Institute, Inc. |
Type vii crispr proteins and systems
|
WO2020223539A1
(en)
|
2019-04-30 |
2020-11-05 |
The Broad Institute, Inc. |
Methods and compositions for barcoding nucleic acid libraries and cell populations
|
WO2020236972A2
(en)
|
2019-05-20 |
2020-11-26 |
The Broad Institute, Inc. |
Non-class i multi-component nucleic acid targeting systems
|
US20220243178A1
(en)
|
2019-05-31 |
2022-08-04 |
The Broad Institute, Inc. |
Methods for treating metabolic disorders by targeting adcy5
|
US20220298501A1
(en)
|
2019-08-30 |
2022-09-22 |
The Broad Institute, Inc. |
Crispr-associated mu transposase systems
|
US20220333208A1
(en)
|
2019-09-03 |
2022-10-20 |
The Broad Institute, Inc. |
Crispr effector system based multiplex cancer diagnostics
|
JP2022547570A
(ja)
|
2019-09-12 |
2022-11-14 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
操作済みのアデノ随伴ウイルスキャプシド
|
EP4031660A1
(de)
|
2019-09-20 |
2022-07-27 |
The Broad Institute, Inc. |
Neuartige typ-vi-crispr-enzyme und systeme
|
KR20220083688A
(ko)
|
2019-09-20 |
2022-06-20 |
더 브로드 인스티튜트, 인코퍼레이티드 |
표적 세포로 카고 전달을 위한 조성물 및 방법
|
US11981922B2
(en)
|
2019-10-03 |
2024-05-14 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
|
CN113881703B
(zh)
*
|
2021-10-11 |
2022-06-21 |
中国人民解放军军事科学院军事医学研究院 |
一种提高cho细胞同源重组效率的方法及其相关产品和应用
|
WO2023081756A1
(en)
|
2021-11-03 |
2023-05-11 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Precise genome editing using retrons
|
WO2023141602A2
(en)
|
2022-01-21 |
2023-07-27 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
WO2024044723A1
(en)
|
2022-08-25 |
2024-02-29 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|